Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Corcept TherapeuticsHAM:HTD +5.78%82 EV-to-OCF is 84.44 as of Jul. 25, 2026, which is 339% above its 10-year median of 19.23. GuruFocus rates HAM:HTD with a GF Score™ of 82/100 and a GF Value™ of €57.32. The stock has 8 warning signs investors should review. Among 1,410 Biotechnology companies, Corcept Therapeutics ranks worse than 97.09% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Corcept Therapeutics's Enterprise Value is €8,709.8 Mil.
Corcept Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was €103.2 Mil. Therefore, Corcept Therapeutics's EV-to-OCF for today is 84.44.
The historical rank and industry rank for Corcept Therapeutics's EV-to-OCF or its related term are showing as below:
HAM:HTD'
s EV-to-OCF Range Over the Past 10 Years
Min: 6.65 Med: 19.23 Max: 82.26
Current: 82.26
During the past 13 years, the highest EV-to-OCF of Corcept Therapeutics was 82.26. The lowest was 6.65. And the median was 19.23.
HAM:HTD's EV-to-OCF is ranked worse than 97.09% of 1410
companies
in the Biotechnology industry
Industry Median: -3.315
vs HAM:HTD: 82.26
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Corcept Therapeutics's PE Ratio (TTM) for today is calculated as:
Corcept Therapeutics's share price for today is €84.98.
Corcept Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.299.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Corcept Therapeutics EV-to-OCF Related Terms
Corcept Therapeutics EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Corcept Therapeutics's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Corcept Therapeutics's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Corcept Therapeutics EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Corcept Therapeutics's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Corcept Therapeutics's EV-to-OCF falls into.
Corcept Therapeutics's current Enterprise Value is €8,709.8 Mil.
Corcept Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €103.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Corcept Therapeutics (HAM:HTD) has a EV-to-OCF of 84.44 as of Jul. 25, 2026. This is 339% above median its historical median of 19.23. Over the past decade, Corcept Therapeutics' EV-to-OCF has ranged from 6.65 to 82.26. According to the industry distribution chart, Corcept Therapeutics ranks #1369 out of 1410 companies in the Biotechnology industry, placing it in the top 97.1%.
Is Corcept Therapeutics' EV-to-OCF too high?
Corcept Therapeutics' current EV-to-OCF of 84.44 is 339% above median its 10-year median of 19.23. Over the past 10 years, this metric has ranged from a low of 6.65 to a high of 82.26. Based on the distribution chart, Corcept Therapeutics ranks #1369 out of 1410 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Corcept Therapeutics has a GF Score™ of 82/100, reflecting its overall financial health beyond just this single metric.
How does Corcept Therapeutics' EV-to-OCF compare to PRAX and IBRX?
According to the Biotechnology industry distribution chart, Corcept Therapeutics ranks #1369 out of 1410 companies for EV-to-OCF. This places Corcept Therapeutics in the lower half of its industry. Historically, Corcept Therapeutics' own EV-to-OCF has ranged from 6.65 to 82.26 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Corcept Therapeutics's current EV-to-OCF is 84.44, which is 339% above median its own 10-year median of 19.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corcept Therapeutics stock overvalued right now?
Corcept Therapeutics (HAM:HTD) has a current EV-to-OCF of 84.44. The stock's GF Value™ is €57.32, compared to a current price of €84.98 — trading 48.3% above its estimated fair value. The current EV-to-OCF is 84.44, which is 339% above median its 10-year median of 19.23. Corcept Therapeutics' overall GF Score™ is 82/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Corcept Therapeutics (HAM:HTD), the current EV-to-OCF is 84.44 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Corcept Therapeutics (HAM:HTD) Overvalued in 2026?
Based on GuruFocus' analysis, Corcept Therapeutics stock appears to be overvalued.
The current stock price of €84.98 is trading 48.3% above its estimated GF Value™ of €57.32.
Key valuation signals for HAM:HTD:
EV-to-OCF: 84.44 (339% above median its 10-year median of 19.23)
GF Value™: €57.32 vs. price of €84.98 (48.3% above fair value)
No single metric tells the full story. See the HAM:HTD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
82GF Score
Get the complete analysis for HAM:HTD
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:HTD has been successfully added to your 
